102 related articles for article (PubMed ID: 22834637)
21. Biological basis of personalized anticoagulation in cancer: oncogene and oncomir networks as putative regulators of coagulopathy.
D'Asti E; Rak J
Thromb Res; 2016 Apr; 140 Suppl 1():S37-43. PubMed ID: 27067976
[TBL] [Abstract][Full Text] [Related]
22. A miR-21 inhibitor enhances apoptosis and reduces G(2)-M accumulation induced by ionizing radiation in human glioblastoma U251 cells.
Li Y; Zhao S; Zhen Y; Li Q; Teng L; Asai A; Kawamoto K
Brain Tumor Pathol; 2011 Jul; 28(3):209-14. PubMed ID: 21618027
[TBL] [Abstract][Full Text] [Related]
23. Targeting miR-21 in glioma: a small RNA with big potential.
Moore LM; Zhang W
Expert Opin Ther Targets; 2010 Nov; 14(11):1247-57. PubMed ID: 20942748
[TBL] [Abstract][Full Text] [Related]
24. Vector-based miR-15a/16-1 plasmid inhibits colon cancer growth in vivo.
Dai L; Wang W; Zhang S; Jiang Q; Wang R; Dai L; Cheng L; Yang Y; Wei YQ; Deng HX
Cell Biol Int; 2012 Aug; 36(8):765-70. PubMed ID: 22574716
[TBL] [Abstract][Full Text] [Related]
25. Anti-cancer effect of R3V6 peptide-mediated delivery of an anti-microRNA-21 antisense-oligodeoxynucleotide in a glioblastoma animal model.
Oh B; Song H; Lee D; Oh J; Kim G; Ihm SH; Lee M
J Drug Target; 2017 Feb; 25(2):132-139. PubMed ID: 27355932
[TBL] [Abstract][Full Text] [Related]
26. Actin-related protein 2/3 complex subunit 5 (ARPC5) contributes to cell migration and invasion and is directly regulated by tumor-suppressive microRNA-133a in head and neck squamous cell carcinoma.
Kinoshita T; Nohata N; Watanabe-Takano H; Yoshino H; Hidaka H; Fujimura L; Fuse M; Yamasaki T; Enokida H; Nakagawa M; Hanazawa T; Okamoto Y; Seki N
Int J Oncol; 2012 Jun; 40(6):1770-8. PubMed ID: 22378351
[TBL] [Abstract][Full Text] [Related]
27. Human miR-31 targets radixin and inhibits migration and invasion of glioma cells.
Hua D; Ding D; Han X; Zhang W; Zhao N; Foltz G; Lan Q; Huang Q; Lin B
Oncol Rep; 2012 Mar; 27(3):700-6. PubMed ID: 22089331
[TBL] [Abstract][Full Text] [Related]
28. Contribution of microRNAs to radio- and chemoresistance of brain tumors and their therapeutic potential.
Chistiakov DA; Chekhonin VP
Eur J Pharmacol; 2012 Jun; 684(1-3):8-18. PubMed ID: 22484336
[TBL] [Abstract][Full Text] [Related]
29. microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs.
Xia H; Qi Y; Ng SS; Chen X; Li D; Chen S; Ge R; Jiang S; Li G; Chen Y; He ML; Kung HF; Lai L; Lin MC
Brain Res; 2009 May; 1269():158-65. PubMed ID: 19265686
[TBL] [Abstract][Full Text] [Related]
30. Integrin control of the transforming growth factor-β pathway in glioblastoma.
Roth P; Silginer M; Goodman SL; Hasenbach K; Thies S; Maurer G; Schraml P; Tabatabai G; Moch H; Tritschler I; Weller M
Brain; 2013 Feb; 136(Pt 2):564-76. PubMed ID: 23378223
[TBL] [Abstract][Full Text] [Related]
31. Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro.
Ren Y; Kang CS; Yuan XB; Zhou X; Xu P; Han L; Wang GX; Jia Z; Zhong Y; Yu S; Sheng J; Pu PY
J Biomater Sci Polym Ed; 2010; 21(3):303-14. PubMed ID: 20178687
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of miR-195 via cyclosporin A in human glioblastoma cells.
Yilaz Susluer S; Biray Avci C; Dodurga Y; Ozlem Dogan Sigva Z; Oktar N; Gunduz C
J BUON; 2015; 20(5):1337-40. PubMed ID: 26537083
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic.
Teplyuk NM; Uhlmann EJ; Gabriely G; Volfovsky N; Wang Y; Teng J; Karmali P; Marcusson E; Peter M; Mohan A; Kraytsberg Y; Cialic R; Chiocca EA; Godlewski J; Tannous B; Krichevsky AM
EMBO Mol Med; 2016 Mar; 8(3):268-87. PubMed ID: 26881967
[TBL] [Abstract][Full Text] [Related]
34. Optimal control strategies of eradicating invisible glioblastoma cells after conventional surgery.
de Los Reyes V AA; Jung E; Kim Y
J R Soc Interface; 2015 May; 12(106):. PubMed ID: 25833239
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.
Cheng CJ; Bahal R; Babar IA; Pincus Z; Barrera F; Liu C; Svoronos A; Braddock DT; Glazer PM; Engelman DM; Saltzman WM; Slack FJ
Nature; 2015 Feb; 518(7537):107-10. PubMed ID: 25409146
[TBL] [Abstract][Full Text] [Related]
36. Current Progress of Phytomedicine in Glioblastoma Therapy.
Shah FH; Salman S; Idrees J; Idrees F; Shah STA; Khan AA; Ahmad B
Curr Med Sci; 2020 Dec; 40(6):1067-1074. PubMed ID: 33428134
[TBL] [Abstract][Full Text] [Related]
37. MicroRNAs as novel biological targets for detection and regulation.
Li J; Tan S; Kooger R; Zhang C; Zhang Y
Chem Soc Rev; 2014 Jan; 43(2):506-17. PubMed ID: 24161958
[TBL] [Abstract][Full Text] [Related]
38. Oligonucleotide-based therapy for neurodegenerative diseases.
Magen I; Hornstein E
Brain Res; 2014 Oct; 1584():116-28. PubMed ID: 24727531
[TBL] [Abstract][Full Text] [Related]
39. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas.
Zhang Y; Roccaro AM; Rombaoa C; Flores L; Obad S; Fernandes SM; Sacco A; Liu Y; Ngo H; Quang P; Azab AK; Azab F; Maiso P; Reagan M; Brown JR; Thai TH; Kauppinen S; Ghobrial IM
Blood; 2012 Aug; 120(8):1678-86. PubMed ID: 22797699
[TBL] [Abstract][Full Text] [Related]
40. RNA Interference Nanotherapeutics for Treatment of Glioblastoma Multiforme.
Singh P; Singh A; Shah S; Vataliya J; Mittal A; Chitkara D
Mol Pharm; 2020 Nov; 17(11):4040-4066. PubMed ID: 32902291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
